The Discounted Cash Flow (DCF) valuation of Mersana Therapeutics Inc (MRSN) is (378.92) USD. With the latest stock price at 10.54 USD, the upside of Mersana Therapeutics Inc based on DCF is -3696.8%.
Based on the latest price of 10.54 USD and our DCF valuation, Mersana Therapeutics Inc (MRSN) is a sell. selling MRSN stocks now will result in a potential gain of 3696.8%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 6.3% - 9.5% | 7.9% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (1,070.34) - (236.78) | (378.92) |
| Upside | -10259.8% - -2347.6% | -3696.8% |